Herceptin
E46088
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
All labels observed (5)
| Label | Occurrences |
|---|---|
| trastuzumab | 8 |
| Herceptin canonical | 3 |
| trastuzumab-dkst | 1 |
| trastuzumab-pkrb | 1 |
| trastuzumab-qyyp | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T363283 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Herceptin Context triple: [Genentech, notableProduct, Herceptin]
-
A.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
B.
Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
-
C.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Herceptin Target entity description: Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
A.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
B.
Pregny-Chambésy
Pregny-Chambésy is a small, affluent municipality on the shores of Lake Geneva in the canton of Geneva, Switzerland, known for hosting several international organizations and diplomatic missions.
-
C.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
D.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
antineoplastic agent
ⓘ
biologic drug ⓘ monoclonal antibody ⓘ targeted therapy ⓘ |
| antibodyIsotype | IgG1 ⓘ |
| antibodyTarget | ERBB2 ⓘ |
| bindsTo |
ERBB2
ⓘ
surface form:
human epidermal growth factor receptor 2
|
| boxedWarningFor |
cardiac toxicity
ⓘ
embryo-fetal toxicity ⓘ |
| FDAApprovalYear | 1998 ⓘ |
| hasATCCode | L01FD01 ⓘ |
| hasBiosimilar |
Herceptin
self-linksurface differs
ⓘ
surface form:
trastuzumab-dkst
trastuzumab-dttb ⓘ Herceptin self-linksurface differs ⓘ
surface form:
trastuzumab-pkrb
Herceptin self-linksurface differs ⓘ
surface form:
trastuzumab-qyyp
|
| hasCASNumber | 180288-69-1 ⓘ |
| hasDrugClass |
HER2 inhibitor
ⓘ
antibody-based therapy ⓘ |
| hasGenericName |
Herceptin
self-linksurface differs
ⓘ
surface form:
trastuzumab
|
| hasMolecularType | humanized monoclonal antibody ⓘ |
| hasUNII | P188ANX8CK ⓘ |
| isAdministeredAs | weight-based dosing ⓘ |
| isContraindicatedWith | severe hypersensitivity to trastuzumab ⓘ |
| isIndicatedAs |
adjuvant therapy
ⓘ
neoadjuvant therapy ⓘ |
| isIndicatedInCombinationWith |
carboplatin
ⓘ
docetaxel ⓘ paclitaxel ⓘ pertuzumab ⓘ |
| isListedOn | World Health Organization Model List of Essential Medicines ⓘ |
| isMarketedBy | Roche ⓘ |
| isProducedBy | Genentech ⓘ |
| isUsedFor |
HER2-positive breast cancer
ⓘ
HER2-positive gastric cancer ⓘ HER2-positive gastroesophageal junction adenocarcinoma ⓘ early-stage HER2-positive breast cancer ⓘ metastatic HER2-positive breast cancer ⓘ |
| mechanismOfAction |
induces antibody-dependent cell-mediated cytotoxicity
ⓘ
inhibits HER2-mediated signaling pathways ⓘ prevents HER2 receptor dimerization ⓘ |
| requiresTestingFor |
HER2 gene amplification
ⓘ
HER2 overexpression ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| seriousAdverseEffect |
cardiomyopathy
ⓘ
congestive heart failure ⓘ infusion-related reactions ⓘ pulmonary toxicity ⓘ |
| targets | HER2 receptor ⓘ |
| wasApprovedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Herceptin Description of subject: Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
Referenced by (14)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
trastuzumab
this entity surface form:
trastuzumab-dkst
this entity surface form:
trastuzumab-pkrb
this entity surface form:
trastuzumab-qyyp
this entity surface form:
trastuzumab
this entity surface form:
trastuzumab
this entity surface form:
trastuzumab
this entity surface form:
trastuzumab
this entity surface form:
trastuzumab
this entity surface form:
trastuzumab
this entity surface form:
trastuzumab